- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT06370715
Badanie LY900014 u dorosłych uczestników chorych na cukrzycę typu 2 w Indiach
26-tygodniowe, wieloośrodkowe, otwarte, jednoramienne badanie fazy 4 oceniające bezpieczeństwo stosowania preparatu Lyumjev u dorosłych pacjentów z cukrzycą typu 2 w Indiach
The purpose of this study is to assess the safety of insulin lispro-aabc in adult participants with Type 2 diabetes mellitus in India.
The study will last about 33 weeks for each participant, including screening (1 week), Lead-in period (4 weeks), treatment period (26 weeks) and follow up period (2 weeks).
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Typ studiów
Zapisy (Rzeczywisty)
Faza
- Faza 4
Kontakty i lokalizacje
Lokalizacje studiów
-
-
Andhra Pradesh
-
Hyderabad, Andhra Pradesh, Indie, 500012
- Osmania Medical College & Hospital
-
Visakhapatnam, Andhra Pradesh, Indie, 530002
- King George Hospital, Visakhapatnam
-
-
Chennai India
-
Royapuram, Chennai India, Indie, 600013
- Diabetes Research Centre
-
-
Gujarat
-
Ahmedabad, Gujarat, Indie, 380007
- Vijyaratna Dibetes Diagnosis Treatment Centre
-
-
Karnataka
-
Bengaluru, Karnataka, Indie, 560043
- Center for Diabetes and Endocrine Care
-
-
Maharashtra
-
Pune, Maharashtra, Indie, 411004
- Sahyadri Super Speciality Hospital
-
Pune, Maharashtra, Indie, 411021
- Chellaram Diabetes Institute
-
-
Rajasthan
-
Bikaner, Rajasthan, Indie, 334003
- S. P. Medical College & A G Hospital
-
Jaipur, Rajasthan, Indie, 302033
- Rajasthan University of Health Sciences
-
-
Tamil Nadu
-
Coimbatore, Tamil Nadu, Indie, 641009
- Kovai Diabetes Speciality Center and Hospital
-
-
Uttar Pradesh
-
Kanpur, Uttar Pradesh, Indie, 208020
- Brij Medical Center Pvt. Ltd.
-
-
West Bengal
-
Kolkata, West Bengal, Indie, 700073
- Medical College & Hospital, Kolkata
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
-
Have Type 2 Diabetes Mellitus (T2DM) for ≥1 year prior to screening
-
Treated for ≥90 days prior to screening with multiple daily injection (MDI) therapy
- on basal insulin or insulin glargine 100 U/mL [Basaglar or Lantus] or insulin glargin 300 U/mL, insulin determir, insulin degludec U-100, or neutral protamine Hagedorn (NPH) insulin) in combination with at least 1 prandial injection of bolus insulin (insulin lispro 100 U/mL or 200 U/mL, insulin aspart, insulin glulisine, regular insulin, fast-acting insulin aspart), or
- premixed analog or human insulin regimens with any basal and bolus insulin
-
May have been treated with up to 3 oral antihyperglycemic medications (OAMs) including metformin, sodium-glucose cotransporter (SGLT)-2 inhibitor in accordance with local regulations. The dose of all OAMs must have been stable for ≥90 days prior to screening
-
Have an HbA1c value ≥7.5% and ≤10% according to the central laboratory at screening
-
Body mass index ≤45.0 kg/m²
-
Have access to a telephone, or alternative means for close monitoring/communications
-
Have refrigeration at home or have ready access to refrigeration for storage of insulin therapy
-
Have a regular wake-sleep schedule (awake-work during the day and sleep during the night)
Exclusion Criteria:
- Having any other condition (including known drug or alcohol abuse, psychiatric disorder including eating disorder) that precludes the subject from following and completing the protocol
- Have been diagnosed, at any time, with type 1 diabetes mellitus (T1DM) or latent autoimmune diabetes in adults
- Have hypoglycemia unawareness as judged by the investigator
- Have had any episode of severe hypoglycemia (defined as requiring assistance due to neurologically disabling hypoglycemia) within the 6 months prior to screening
- Have had 1 or more episodes of diabetic ketoacidosis or hyperglycemic hyperosmolar state within the 6 months prior to screening
- Have a known diagnosis of secondary diabetes (for example, diabetes caused by hemochromatosis, acromegaly, chronic pancreatitis, or pancreatectomy)
- Excessive insulin resistance defined as having received a total daily dose of insulin >2.0 U/kg at the time of screening
- Have a history of or are being evaluated for bariatric surgery including Roux-en-Y gastric bypass surgery, gastric banding, and/or gastric sleeve
- Have cardiovascular disease, within the past 6 months prior to screening, defined as stroke, decompensated heart failure (New York Heart Association Class III or IV), myocardial infarction, unstable angina pectoris, or coronary arterial bypass graft
- History of renal transplantation
- Currently receiving renal dialysis
- Serum creatinine >2.0 mg/dL (177 µmol/L) at screening
- Have obvious clinical signs or symptoms of liver disease (for example, acute or chronic hepatitis or cirrhosis), or elevated liver enzyme measurements
- Have active or untreated malignancy, have been in remission from clinically significant malignancy (other than basal cell or squamous cell skin cancer) for less than 5 years, or are at an increased risk for developing cancer or a recurrence of cancer in the opinion of the investigator
- Have had a blood transfusion or severe blood loss within 90 days prior to screening or have known hemoglobinopathy, anemia, or any other traits known to interfere with measurement of HbA1
- Have presence of clinically significant gastrointestinal disease (for example, clinically active gastroparesis associated with wide glucose fluctuations) in the investigator's opinion
- Have used thiazolidinediones, glucagon-like peptide 1 receptor agonist, or pramlintide within 90 days prior to screening
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Nie dotyczy
- Model interwencyjny: Zadanie dla jednej grupy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: Insulin Lispro-aabc
Participants received subcutaneous injections of insulin lispro-aabc 100 units/millilitre (U/mL) immediately (0 to 2 minutes) before each meal, in combination with once-daily insulin glargine 100 U/mL as basal insulin, during the 26-week treatment period. |
Administered subcutaneously
Inne nazwy:
Administered subcutaneously
Inne nazwy:
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Percentage of Participants With at Least 1 Documented Hypoglycemic Event With Blood Glucose <54 Milligrams Per Deciliter (mg/dL)
Ramy czasowe: Baseline through Week 26
|
The percentage of participants with at least 1 documented hypoglycemic event was calculated as the number of participants with >=1 documented hypoglycemic event divided by the total number of participants, multiplied by 100. |
Baseline through Week 26
|
|
Rate of Documented Hypoglycemia With Blood Glucose <54 mg/dL
Ramy czasowe: Baseline through Week 26
|
Rate of documented hypoglycemia (events/participant/year) was calculated as the sum of documented hypoglycemic episodes divided by the cumulative days on treatment from all participants, multiplied by 365. |
Baseline through Week 26
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Percentage of Participants With Severe Hypoglycemia
Ramy czasowe: Baseline through Week 26
|
|
Baseline through Week 26
|
|
Percentage of Participants With at Least 1 Nocturnal Hypoglycemic Event With Blood Glucose <54 mg/dL
Ramy czasowe: Baseline through Week 26
|
|
Baseline through Week 26
|
|
Rate of Nocturnal Hypoglycemia With Blood Glucose <54 mg/dL
Ramy czasowe: Baseline through Week 26
|
|
Baseline through Week 26
|
|
Percentage of Participants With at Least 1 Nocturnal Hypoglycemic Event With Blood Glucose <70 mg/dL
Ramy czasowe: Baseline through Week 26
|
|
Baseline through Week 26
|
|
Rate of Nocturnal Hypoglycemia With Blood Glucose <70 mg/dL
Ramy czasowe: Baseline through Week 26
|
|
Baseline through Week 26
|
|
Percentage of Participants With at Least 1 Documented Hypoglycemic Event With Blood Glucose <70 mg/dL
Ramy czasowe: Baseline through Week 26
|
The percentage of participants with at least 1 documented hypoglycemic event was calculated as the number of participants with >=1 documented hypoglycemic event divided by the total number of participants, multiplied by 100. |
Baseline through Week 26
|
|
Rate of Documented Hypoglycemia With Blood Glucose <70 mg/dL
Ramy czasowe: Baseline through Week 26
|
Rate of documented hypoglycemia (events/participant/year) was calculated as the sum of documented hypoglycemic episodes divided by the cumulative days on treatment from all participants, multiplied by 365. |
Baseline through Week 26
|
|
Change From Baseline in Body Weight
Ramy czasowe: Baseline, Week 26
|
Baseline, Week 26
|
|
|
Change From Baseline in Hemoglobin A1c (HbA1c)
Ramy czasowe: Baseline, Week 26
|
HbA1c is the glycosylated fraction of hemoglobin A. It is measured to identify average plasma glucose concentration over prolonged periods of time. |
Baseline, Week 26
|
|
Percentage of Participants Achieving HbA1c < 7%
Ramy czasowe: Week 26
|
HbA1c is the glycosylated fraction of hemoglobin A. It is measured to identify average plasma glucose concentration over prolonged periods of time. |
Week 26
|
|
Change From Baseline in Insulin Treatment Satisfaction Questionnaire (ITSQ) Score
Ramy czasowe: Baseline, Week 26
|
The ITSQ is a 22-item questionnaire that assesses treatment satisfaction for participants taking insulin under 5 domains: Inconvenience of Regimen [5 items], Lifestyle Flexibility [3 items], Glycemic Control [3 items], Hypoglycemic Control [5 items], Insulin Delivery Device [6 items]. Each Item is measured on a 7-point scale. The overall score is calculated as the mean of all 22 items and transformed to a scale of 0 to 100 using the formula: 100*[(7 - raw overall score)/6], with higher scores indicating better treatment satisfaction. |
Baseline, Week 26
|
|
Change From Baseline in 1- and 2-hour Postprandial Glucose (PPG) Values Estimated From Self-monitored Blood Glucose (SMBG) Values
Ramy czasowe: Baseline, Day 3 of Week 20
|
Baseline, Day 3 of Week 20
|
|
|
Change From Baseline in Bolus Insulin Dose, Basal Insulin Dose
Ramy czasowe: Baseline, Week 20
|
|
Baseline, Week 20
|
|
Change From Baseline in Basal to Bolus Insulin Dose Ratio
Ramy czasowe: Baseline, Week 20
|
Basal to Bolus insulin dose ratio, calculated as the basal insulin dose divided by the basal insulin dose.
|
Baseline, Week 20
|
|
Change From Baseline in 9-Point Self-Monitored Blood Glucose (SMBG) Values
Ramy czasowe: Baseline, Week 20
|
SMBG measurements were taken at 9 time points: fasting, 1 hour post-breakfast, 2 hours post-breakfast, pre-lunch, 1 hour post-lunch, 2 hours post-lunch, pre-dinner, 1 hour post-dinner, and 2 hours post-dinner. The SMBG value was calculated as the average of the corresponding SMBG measurements collected on Days 1, 2, and 3 across cumulative non-missing data days. |
Baseline, Week 20
|
Współpracownicy i badacze
Sponsor
Współpracownicy
Śledczy
- Dyrektor Studium: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
- Choroby układu hormonalnego
- Choroby metaboliczne
- Zaburzenia metabolizmu glukozy
- Choroby żywieniowe i metaboliczne
- Cukrzyca typu 2
- Cukrzyca
- Hormony
- Hormony, substytuty hormonów i antagoniści hormonów
- Hormony peptydowe
- Peptydy
- Aminokwasy, peptydy i białka
- Insulina, długo działająca
- Insuliny
- Hormony trzustkowe
- Insulina glargine
Inne numery identyfikacyjne badania
- 18269
- I8B-MC-ITTA (Inny identyfikator: Eli Lilly and Company)
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Ramy czasowe udostępniania IPD
Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
Kryteria dostępu do udostępniania IPD
A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Typ informacji pomocniczych dotyczących udostępniania IPD
- PROTOKÓŁ BADANIA
- SOK ROŚLINNY
- CSR
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
produkt wyprodukowany i wyeksportowany z USA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .